RECRUITING

Study of the Role of Genetic Modifiers in Hemoglobinopathies

Talk to us

Conditions

Sickle Cell DiseaseThalassemia, BetaThalassemia AlphaHemoglobinopathiesGWASthalassemiagenetic modifiers

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study will investigate the role of genetic modifiers in hemoglobinopathies through a large-scale, multi-ethnic genome-wide association study (GWAS).

Official Title

Study of the Role of Genetic Modifiers in Hemoglobinopathies

Quick Facts

Study Start:2022-10-01
Study Completion:2027-09-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05799118

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:2 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Clinical diagnosis of an inherited hemoglobinopathy, including sickle cell disease (SCD), β-thalassemia, and α-thalassemia; all genotypes will be considered.
  2. * Age ≥ 2 years old at the time of the collection of the phenotypic data.
  3. * There will be no limits on study participants in terms of gender, ethnicity, morbidities.
  1. * Patients treated with stem cell transplantation or genetic therapy.
  2. * Age \< 2 years old at the time of the collection of the phenotypic data.
  3. * Patient or legal representative for minors unwilling or unable to give consent.

Contacts and Locations

Study Contact

Petros Kountouris, PhD
CONTACT
22392623
admin@inherentnetwork.org

Principal Investigator

Petros Kountouris, PhD
PRINCIPAL_INVESTIGATOR
Cyprus Institute of Neurology and Genetics

Study Locations (Sites)

Boston Children's Hospital
Boston, Massachusetts, 02115
United States

Collaborators and Investigators

Sponsor: Cyprus Institute of Neurology and Genetics

  • Petros Kountouris, PhD, PRINCIPAL_INVESTIGATOR, Cyprus Institute of Neurology and Genetics

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-10-01
Study Completion Date2027-09-30

Study Record Updates

Study Start Date2022-10-01
Study Completion Date2027-09-30

Terms related to this study

Keywords Provided by Researchers

  • GWAS
  • thalassemia
  • sickle cell disease
  • genetic modifiers

Additional Relevant MeSH Terms

  • Sickle Cell Disease
  • Thalassemia, Beta
  • Thalassemia Alpha
  • Hemoglobinopathies